药剂教研室现有教师9人,其中教授1人,副教授3人,讲师4人,助教1人;学历结构:博士学位2人,在读博士1人,硕士学位6人。
[科研方向]
纳米靶向制剂的研究
药物新制剂新材料的研究
药物缓释控释制剂的研究
中药新剂型的开发与研究
经皮缓控释贴剂
结肠靶向制剂
[承担课题]
课题来源 | 项目名称 | 编号 |
国家自然基金面上项目 | 糖/抗体/肽靶向纳米载体的表面(层)物质基础对缺血心肌miR-1/MMP9/Glut1摄取调控机制 | 81671814 |
国家自然青年科学基金项目 | 抗体修饰的miR-21脂质体靶向急性缺血心肌的研究 | 81402865 |
国家自然青年科学基金项目 | 靶向结直肠肿瘤的TK-VLPs递药系统的构建及其靶向机制的研究 | 81703426 |
国家自然青年科学基金项目 | lncRNA O11RIK在白藜芦醇抗动脉粥样硬化中的作用及机理研究 | 81503069 |
黑龙江自然基金重点项目 | 微环境响应性心靶向纳米复合体的构建与疗效研究 | ZD2016013 |
黑龙江省教育厅项目 | 新型脑区靶向性脂质体的分布调控及机制研究 | 12541348 |
黑龙江省教育厅项目 | 布地奈德菌群触发型结肠靶向片的研究 | 12511321 |
黑龙江省自然科学基金项目 | 脂质体治疗心律失常的研究 | D201031 |
黑龙江省自然科学基金 | 抗体介导的脂质体靶向急性缺血心肌的研究 | QC2015130 |
黑龙江省科学基金青年科学基金项目 | MALAT1在动脉粥样硬化中的作用及机理研究 | QC2016112 |
黑龙江省普通本科高等学校青年创新人才培养计划项目 | 双靶修饰脂质体治疗脑胶质瘤的研究 | UNPYSCT-2015036 |
黑龙江省普通本科高等学校青年创新人才培养计划项目 | lncRNA GAS5抗动脉硬化的机制研究 | UNPYSCT-2016040 |
黑龙江省卫生厅项目 | 伏立康唑纳米颗粒治疗真菌感染的研究 | 2005-26 |
黑龙江省卫生厅项目 | 表皮生长因子脂质体透皮贴剂的研究 | 2011.236 |
黑龙江省卫生计生委 | 基于细小病毒VLPs纳米药物载体的构建及其稳定性研究 | 2017-170 |
黑龙江省卫生计生委科研课题 | 纳米生物活性玻璃缓控释贴剂的研究 | 2012-785 |
中国博士后基金面上项目 | lncRNA AI662270在动脉粥样硬化中的作用及机理研究 | 2015M571449 |
中国博士后特别资助项目 | lncRNA GAS5降低内皮细胞自噬抗动脉硬化的机制研究 | 2016T90316 |
黑龙江省博士后项目 | 抗cTnI单抗修饰纳米粒心肌靶向性的研究 | LRB08-313 |
黑龙江省博士后基金青年项目 | LBH-Z15160 | |
大庆高新技术产业开发区管理委员会经济科技发展局基金 | 心肌靶向制剂治疗心律失常的研究 | DQGX08YF035 |
大庆市指导性科技计划项目 | 双靶脂质体体内分布研究 | zdy-2016-083 |
哈尔滨医科大学于维汉院士杰出青年培养基金 | 心肌靶向制剂的设计与相关机理研究 | |
于维汉院士杰出青年培养基金 | 叶酸/糖双修饰脑靶向脂质体组织分布及分子机制研究 | DQYWH201603 |
哈尔滨医科大学伍连德校青年基金项目 | 菌群触发型结肠定位给药制剂的研究 | WLD-QN1111 |
哈尔滨医科大学种子基金项目 | 长寿基因SIRT1调控肺动脉高压血管重构分子机制研究 | DQ201403 |
哈尔滨医科大学创新科学研究基金 | miR-21纳米复合体对急性心肌梗死的治疗研究 | |
校伍连德基金项目 | lncRNA GAS5降低内皮细胞自噬抗动脉粥样硬化的机制研究 | |
哈尔滨医科大学(大庆)优秀硕导基金 | 心肌靶向制剂研究 | DSJJ2015004 |
哈医大大庆校区 种子基金 | MAN+6-巯基嘌呤修饰的脂质体靶向脑胶质瘤的研究 | DQ201203 |
哈医大大庆校区校内科研基金 | 心肌靶向纳米复合体的构建及相关作用机制的研究 | 2018XN-22 |
哈医大大庆校区校内科研基金 | 异端双修饰单一分布聚乙二醇衍生物的合成及其应用 | 2018XN-24 |
横向课题 | 抗感泡腾片的工艺研究 |
[新药&专利]
新药
先后获得新药临床批件4项,分别为瑞舒伐他汀钙胶囊(2005L03444)、伏立康唑分散片(2005L02072)、米格列奈钙胶囊(2005L04025)及瑞舒伐他汀钙分散片(2005L04479);获得新药证书1项:盐酸舍曲林胶囊(国药证字H20051808)。
专利
1.一种基于PPV病毒样颗粒的纳米递药系统及其制备方法和应用.专利号: CN201510593848.4.
2.盐酸氨溴索干粉吸入剂及其制备方法.专利号: 200710159344.7.
3.动物组织石蜡切片的绿色环保制作技术.专利号:CN201110175687.9.
4.微需氧/厌氧微生物培养器.专利号:CN201220436839.6.
5.一种心脑双靶向脂质体及其制备方法和应用.申请号:201810299429.3
6.一种抗心肌肌钙蛋白抗体修饰并载有miR-21的脂质体及其制备方法和应用.申请号:201810898620.X
7.一种乙酰化糖酯-聚乙二醇-磷脂酰乙醇胺共轭物及其制备方法与应用.申请号: 201810301839.7
8.糖-聚乙二醇-DSPE偶联化合物及其制备方法与应用.申请号:201811062535.6
[英文论作]
1. Poovaiah N, Davoudi Z, Peng HS, Schlichtmann B, Mallapragada SK, Narasimhan B. and Wang Q.* Treatment of Neurodegenerative Disorders through the Blood-brain Barrier using Nanocarriers. Nanoscale. 2018 (IF=7.713)
2. Ren YC# , Jiang L #, Yang SM, Gao SN, Yu H, Hu J, Hu DD, Mao WB, Peng HS*, and Zhou YL* Design and preparation of a novel colon-targeted tablet of hydrocortisone. Braz. J. Pharm. Sci. 2017; 53(1) : e15009.
3.Weng M, Wu D, Yang C, Peng H, Wang G*, Wang T, Li X*.Noncoding RNAs in the development, diagnosis, and prognosis of colorectal cancer. Transl Res. 2017; 181:108-120. (IF=4.652)
4. Liu DM, Tang SK, Wang GT, Li MH, Liu XY, Tao HQ, Ren YC, Jiang CL*, Peng HS*, and Lian MM*. The modification of mannose derivation improves the distribution of liposomes in transient ischemia reperfusion mice brain via GLUT1. J. Biomed Nanotech. 2017; 13(17): 638-654. (IF=4.521)
5. Ren YC, Mu Y, Jiang L, Yu Hui, Yang SM, Zhang Y, Wang JZ, Zhang H, Sun HN, Xiao CH, Peng HS, Zhou YL, Lu WY. Multifunctional TK-VLPs nanocarrier for tumor-targeted delivery. Int J Pharm. 2016; 11;502(1-2):249-57. (IF=3.65)
6. Ren YC, Mu Y, Song YP, Xie JX, Yu H, Gao SN, Li S, Peng HS, Zhou YL, and Lu WY. A new peptide ligand for colon cancer targeted delivery of micelles. Drug Deliv. 2016;23(5):1763-72. (IF=2.558)
7. Peng HS1, Liu XY1, Wang GT1, Li MH, Bratlie KM, Cochran E, and Wang Q. Polymeric Multifunctional Nanomaterials for Theranostics. J. Mater. Chem. B. 2015. 3(34):6856-6870 (IF=4.726)
8. Cao JY, Wang R, Gao N, Li MH, Tian XY, Yang WL, Ruan Y, Zhou CL, Wang GT, Liu XY, Tang SK, Yu Y, Liu Y, Sun GY, Peng HS*, and Wang Q*. A7RC peptide modified paclitaxel liposomes dually target breast cancer. Biomaterials Science. 2015,3(12): 1545-1554 (IF=3.831)
9. Ikoba U1, Peng HS1, Li HC1, Miller C, Yu CX, and Wang Q*. Nanocarriers in Therapy of Infectious and Inflammatory Diseases. Nanoscale. 2015. 7(10): 4291-4305 (IF=7.394)
10. Peng HS, Wang C, Xu XY, Yu CX, and Wang Q*. An Intestinal Trojan Horse for Gene Delivery. Nanoscale. 2015. 7(10): 4354-4360. (IF=7.394)
11. Peng HS, Poovaiah N, Cochran E, Forrester M, and Wang Q. Ex Vivo Culture of Primary Intestinal Stem Cells in Collagen Gels and Foams. Acs Biomaterials science and engineering. 2015. 1(1): 37-42. (IF=3.234)
12. Wang Q1, Cheng H1,*, Peng HS, Zhou H, Li Peter Y, and Langer R*. Non-genetic Engineering of Cells for Drug Delivery and Cell-based Therapy. Advanced drug delivery review. 2015. 91: 125-140 (IF=15.038)
13. Peng HS1, Liu XP1, Wang R1, Jia F, Dong L, and Wang Q* Emerging Nanostructured Materials for Musculoskeletal Tissue Engineering. J. Mater. Chem. B. 2014. 2(38): 6435-6461. (IF=4.726)
14. Sun SL, Guo L, Ren YC, Wang B, Li RH, Qi YS, Yu H, Chang ND, Li MH, and Peng HS*. Anti-apoptosis effect of polysaccharide isolated from the seeds of Cuscuta chinensis Lam on cardiomyocytes in aging rats. Mol, Biol, Rep. 2014. 41(9): 6117-6124. (IF=2.024)
15. Zhen XE, Zong M, Gao SN, Cao YG, Jiang L, Chen SX, Wang K, Sun SQ, Peng HS, Bai YH, Li S*.Preparation and Characterization of a novel aspirin derivative with anti-thrombotic and gastric mucosal protection properties. PLOS ONE, 2014, 9(6): e98513. (IF=3.234)
16. Du D, Chang ND, Sun SL, Li MH, Yu H, Liu MF, Liu XY, Wang GT, Li HC, Liu XP, Geng SL, Wang Q*, and Peng HS*. The Role of Glucose Transporters in Distribution of Liposomes Modified with P-Aminophenyl - α-D-Mannopyranoside in Mice Brain. J. Control. Release. 2014; 182:99-110. (IF=7.705)
17. Liu MF, Li MH, Wang GT, Liu XY, Liu DM, Peng HS*, and Wang Q* Heart-targeted nanoscale drug delivery systems. J. Biomed. Nanotech. 2014; 10: 2038-2062. (IF=5.338)
18. Liu MF, Li MH, Sun SL, Li BX, Du D, Sun JL, Cao FY, Li HC, Jia F, Wang T, Chang ND, Yu H, Wang Q, and Peng HS*. The use of antibody modified liposomes loaded with AMO-1 to deliver oligonucleotides to ischemic myocardium for arrhythmia therapy. Biomaterials. 2014; 35(11): 3697-3707. (IF=8.557)
19. Li MH1, Yu H1, Wang TF1, Chang ND, Zhang JQ, Du D, Liu MF, Sun SL, Wang R, Tao HQ, Shen ZY, Wang Q*, and Peng HS*. Tamoxifen Embedded in Lipid Bilayer Improved the Oncotarget of Liposomal Daunorubicin in vivo. J. Mater. Chem. B. 2014; 2: 1619-1625. (IF=4.726)
20. Li MH, Deng HB, Peng HS*, Wang Q*. Functional Nanoparticles in Targeting Glioma Diagnosis and Therapies. J. Nanosci. Nanotech. 2014; 14(1):415-432. (IF=1.556)
21. Niu J1, Xing C1, Yan C, Liu H, Cui Y, Peng H, Chen Y, Li D, Jiang C, Li N, Yang H*. Lentivirus-mediated CD/TK fusion gene transfection neural stem cell therapy for C6 glioblastoma. Tumor Biol. 2013; 34(6): 3731-3741. (IF=3.611)
22. Hao ZF, Cui YX, Li MH, Du Dan, Liu MF, Tao HQ, Li S, Cao FY, Chen YL, Lei XH, Wang L, Zhu DL, Peng HS*, Jiang CL*. Liposomes Modified with P-Aminophenyl- α-D-Mannopyranoside: A Carrier for Targeting Cerebral Functional Regions in Mice. Eur. J. Pharm. Biopharm. 2013; 84(3): 505-516. (IF=3.383)
23. Tao HQ, Li MH, Yu H, Liu MF, Du Dan, Sun SL, Yang HC, Wang YM, Ye W, Yang LZ, Zhu DL, Jiang CL*, Peng HS*. HP-β-CD-PLGA nanoparticles improve the penetration and bioavailability of puerarin and enhance the therapeutic effects on brain ischemia–reperfusion injury in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 2013; 386(1): 61-70. (IF=2.471)
24. Shao M, Sun SL, Li MH, Li BX, Yu H, Shen ZY, Ren YC, Hao ZF, Chang ND, Peng HS*, Yang BF*. The liposomal daunorubicin modified with tamoxifen: improving the stability, uptake and biodistribution of carriers. J. Liposome Res. 2012; 22(2): 168-176. (IF=1.822)
25. Qi X, Shao M, Peng HS, Bi ZG, Su ZQ, Li HL. In vitro differentiation of bone marrow stromal cells into neurons and glial cells and differential protein expression in a two-compartment bone marrow stromal cell/neuron co-culture system. J. Clin. Neurosci. 2010; 17 (7): 908–913. (IF=1.378)
26. Liu XJ, Zhang JF, Sun B, Peng HS, Kong QF, Bai SS, Liu YM, Wang GY, Wang JH, Li HL. Reciprocal effect of mesenchymal stem cell on experimental autoimmune encephalomyelitis is mediated by transforming growth factor-beta and interleukin-6. Clin. Exp. Immunol. 2009;158(1):37-44. (IF=3.037)
27. Kong QF, Sun B, Bai SS, Zhai DX, Wang GY, Liu YM, Zhang SJ, Li R, Zhao W, Sun YY, Li N, Wang Q, Peng HS, Jin LH, Li HL. Administration of bone marrow stromal cells ameliorates experimental autoimmune myasthenia gravis by altering the balance of Th1/Th2/Th17/Treg cell subsets through the secretion of TGF-β. J. Neuroimmunol. 2009, 207 (1-2): 83-91. (IF=2.467)
28. Zhai DX, Kong QF, Xu WS, Bai SS, Peng HS, Zhao K, Li GZ, Wang DD, Sun B, Wang JH, Wang GY, Li HL.. RAGE expression is up-regulated in human cerebral ischemia and pMCAO rats. Neurosci. Lett. 2008, 445(1):117-121. (IF=2.030)
29. Zhao W, Wang Y, Wang DD, Sun B, Wang GY, Wang JH, Kong QF, Wang Q, Peng HS, Jin LH, Li HL. TGF-beta expression by allogeneic bone marrow stromal cells ameliorates diabetes in NOD mice through modulating the distribution of CD4+ T cell subsets. Cell Immunol. 2008, 253(1-2): 23-30. (IF=1.924)
30. Peng HS1, Liu XJ1, Lv GX, Sun B, Kong QF, Zhai DX, Wang Q, Zhao W, Wang GY, Wang DD, Li HL, Jin LH, Kostulas N. Voriconazole into PLGA Nanoparticles: Improving agglomeration and antifungal efficacy. Int. J. Pharm. 2008, 352(1-2): 29-35. (IF=3.65)
31. Peng HS*, Du D, Zhang JQ. Liposomes modified with P-aminophenyl-α-d-mannopyranoside: a promising delivery system in targeting the brain. Ther. Deliv. 20; 4(12): 1475-1477.
32. Liu XY, Peng HS, Wang Q*. Surface engineering of liposomal formulations for targeted drug delivery. Chemical Engineering & Process Techniques. 2014, 2(1): 1025-1027.
33. Li MH, Wang Guangtian Li HC, and Peng HS*. How to deliver therapeutics or imaging agents to the infarcted heart? Austin therapeutics. 2015.
34. Hu DD, Tang SK, Peng HS *, and Wang Q*.The Bright Future of Liposome Mediated Drug Delivery . Biochemistry & Physiology. 2014. 4(1): 1000e133-1000e134.
35. Chen G, Ye G, Zhang X, Liu X, Tu Y, Ye Z, Liu J, Guo Q, Wang Z, Wang L, Dong S, Fan Y*. Metabolomics Reveals Protection of Resveratrol in Diet-Induced Metabolic Risk Factors in Abdominal Muscle. Cell Physiol Biochem.2018;45(3):1136-1148. (IF=5.5)
36. Yu L, Tu Y, Jia X, Fang K, Liu L, Wan L, Xiang C, Wang Y, Sun X, Liu T, Yu D, Cao W, Song Y, Fan Y*. Resveratrol Protects Against Pulmonary Arterial Hypertension in Rats via Activation of Silent Information Regulator 1. Cell Physiol Biochem. 2017;42(1):55-67. (IF=5.5)
37. Fan Y, Liu L, Fang K, Huang T, Wan L, Liu Y, Zhang S, Yan D, Li G, Gao Y, Lv Y, Chen Y, Tu Y. Resveratrol Ameliorates Cardiac Hypertrophy by Down-regulation of miR-155 Through Activation of Breast Cancer Type 1 Susceptibility Protein. J Am Heart Assoc. 2016 Apr 22;5(4). (IF=4.863)
38. Fan Y#, Chen M#, Meng J, Yu L, Tu Y, Wan L, Fang K, Zhu W*. Arsenic trioxide and resveratrol show synergistic anti-leukemia activity and neutralized cardiotoxicity. PLoS One. 2014 Aug 21;9(8):e105890. (IF=3.057)
39. Fan Y, Wang C, Zhang Y, Hang P, Liu Y, Pan Z, Wang N, Du Z*. Genistein ameliorates adverse cardiac effects induced by arsenic trioxide through preventing cardiomyocytes apoptosis. Cell Physiol Biochem. 2013;31(1):80-91. (IF=4.652)
40. Ye G, Chen G, Gao H, Lin Y, Liao X, Zhang H, Liu X, Chi Y, Huang Q, Zhu H, Fan Y*, Dong S*. Resveratrol inhibits lipid accumulation in the intestine of atherosclerotic mice and macrophages. J Cell Mol Med. 2019 Apr 7. (IF=4.302)
41. Tu Y, Qiu Y, Liu L, Huang T, Tang H, Liu Y, Guo W, Jiang H, Fan Y*, Yu B*. mi R -15a/15b Cluster Modulates Survival of Mesenchymal Stem Cells to Improve Its Therapeutic Efficacy of Myocardial Infarction. J Am Heart Assoc. 2019 Jan 8;8(1):e010157. (IF=4.45)
42. Gao W, Dong X, Xie N, Zhou C, Fan Y, Chen G, Wang Y, Wei T*, Zhu D. Dehydroabietic acid isolated from Commiphora opobalsamum causes endothelium-dependent relaxation of pulmonary artery vi PI3K/Akt-eNOS signaling pathway. Molecules. 2014 Jun 23;19(6):8503-17. (IF=2.465)
43. Tu Y, Wan L, Fan Y, Wang K, Bu L, Huang T, Cheng Z, Shen B*. Ischemic postconditioning-mediated miRNA-21 protects against cardiac ischemia/reperfusion injury via PTEN/Akt pathway. PLoS One. 2013 Oct 3;8(10):e75872. (IF=3.057)
44. Shan H#, Zhang Y#, Cai B, Chen X, Fan Y, Yang L, Chen X, Liang H, Zhang Y, Song X, Xu C, Lu Y, Yang B, Du Z*. Upregulation of microRNA-1 and microRNA-133 contributes to arsenic-induced cardiac electrical remodeling. Int J Cardiol. 2013 Sep 10;167(6):2798-805. (IF=4.638)
45. Wang S#, Han HM#, Jiang YN, Wang C, Song HX, Pan ZY, Fan K, Du J, Fan YH, Du ZM, Liu Y*. Activation of cardiac M3 muscarinic acetylcholine receptors has cardioprotective effects against ischaemia-induced arrhythmias. Clin Exp Pharmacol Physiol. 2012 Apr;39(4):343-9. (IF=2.092)
46. Pan Z#, Guo Y#, Qi H, Fan K, Wang S, Zhao H, Fan Y, Xie J, Guo F, Hou Y, Wang N, Huo R, Zhang Y, Liu Y*, Du Z*. M3 subtype of muscarinic acetylcholine receptor promotes cardioprotection via the suppression of miR-376b-5p. PLoS One. 2012;7(3):e32571. (IF=3.057)
47.Ren Yachao, Zhan C, Gao J, Zhang M, Wei X, Ying M, Liu Z, Lu W. A d-Peptide Ligand of Integrins for Simultaneously Targeting Angiogenic Blood Vasculature and Glioma Cells. Mol Pharm. 2018,15(2):592-601. (IF=4.556)
48.Ren Yachao, Wang Lei, He Haibing, Tang Xing.Pulmonary Selectivity and Local Pharmacokinetics of Ambroxol Hydrochloride Dry Powder Inhalation in Rat. Journal of Pharmaceutical Science (US),2009,98(5):1797-803. (IF=2.641)
49.Ren Yachao, Yu Chaoqun, Meng Kangkang, Tang Xing. Influence of formulation and preparation process on Ambroxol Hydrochloride dry powder inhalation characteristics and aerosolization properties. Drug Development and Industrial Pharmacy, 2008,34(9):984-91. (IF=2.429)
50.Yulong Zhou, Yachao Ren, Yanlong Cong, Yu Mu, Renfu Yin, Zhuang Ding. Autophagy induced by bovine viral diarrhea virus infection counteracts apoptosis and innate immune activation.Arch Virol, 2017,162:3103-3118. (IF=2.16)
51.Zhou Yulong, Ren Yachao, Fan Chunling, etal. Survey of Mycotic Mastitis of Dairy Cows from Heilongjiang Province, China. Trop Anim Health Prod, 2013,45(8):1709-1714. (IF=0.87)
52.Gao Jie, Xie Cao, Zhang Mingfei, Wei Xiaoli, Yan Zhiqiang, Ren Yachao, Ying Man, Lu Weiyue.RGD-modified lipid disks as drug carriers for tumor targeted drug delivery. Nanoscale. 2016, 8(13):7209-7216. (IF=7.376)
53.Li Xue, Xie Zuoxu, Xie Cao, Lu Weiyue, Gao Chunli, Ren Henglei, Ying Man, Wei Xiaoli, Gao Jie, Su Bingxia, Ren Yachao, Liu Min. D-SP5 Peptide-Modified Highly Branched Polyethylenimine for Gene Therapy of Gastric Adenocarcinoma. Bioconjug Chem. 2015,26(8):1494-503. (IF=4.5)
54.Sun Shouli, Guo Li, Ren Yachao, etal. Anti-apoptosis effect of polysaccharide isolated from the seeds of Cuscuta chinensis Lam on cardiomyocytes in aging rats. Mol Biol Rep. 2014,41(9):6117-24. (IF=1.698)
55.Zhao Min, You Yu, Ren Yachao, Zhang Yu, Tang Xing. Formulation, characteristics and aerosolization performance of azithromycin DPI prepared by spray-drying.2008,187(3):214-221
[中文论作]
1.扈丹丹,刘肖莹,李明慧,彭海生.纳米技术治疗脑胶质瘤的研究进展[J].中国医药导报,2018;15(12):25-27.
2.王娜,唐淑坤,张文远,张大鹏,高赛男,李明慧,彭海生.纳米粒子治疗脑胶质瘤的研究进展[J].中国医药导报,2018;24(14):2792-2796.
3.杨伟丽,刘肖莹,于辉, 王广天,李明慧,彭海生.AMO-1 脂质体对缺血性心律失常大鼠的治疗研究[J].中国医药导报,2016;13(20):8-11.
4.杨伟丽,王广天,于辉,常乃丹,梁玲,刘肖莹,李明慧,彭海生.纳米靶向给药系统的研究进展[J].中国医药导报,2016;13(28):32-35.
5.李明慧, 汪晴. 格拉司琼贴片含量和体外释放度测定[J].药学服务与研究 Pharm Case Res 2010 Dec;10(6)426-428
6.张晴,汪清,李明慧,等.乌头碱、人参皂苷Rg1与延胡索乙素经皮渗透及协同促渗研究[J]. 中国中医药信息杂志 2009(16)36-39
7.任亚超,周玉龙,于辉,彭海生.药剂学青年专业教师担任兼职班主任工作浅谈.心理医生,2017,30.
8.任亚超,周玉龙,于辉,彭海生.药剂学专业创新创业人才培养浅谈.医药卫生(文摘版),2017,01:382.
9.任亚超,赵祎镭,周玉龙,于辉,彭海生. ,大医生, 2017 (5).
10.任亚超,叶莉,罗敏等.氢化可的松结肠靶向片包衣处方筛选及其释放机制研究.中国药房, 2014,25 (13):1193-1196.
11.周玉龙,任亚超,朱占波等.牛副流感病毒3型HN蛋白的表达及间接ELISA方法建立.中国病毒学报,2012,12(1): 23-28.(共同一作)
12.任亚超,李森,彭海生,申志英,于辉,蒋蕾,唐星.盐酸氨溴索干粉吸入剂理化性质研究及初步稳定性考察[J].中国药房,2011,22(29):2735-2737.
13.任亚超,王蕾,孟康康,唐星.盐酸氨溴索干粉吸入剂的制备工艺[J]. 沈阳药科大学学报,2008,25(7):519-523.
14.周玉龙,吴海涛,任亚超.牛副流感病毒3型的分离鉴定及感染牛抗体消长规律的研究[J].中国人兽共患病学报,2011,27(1): 23-28.
15.申志英,任亚超,彭海生,孙世芹.药学生核心素质及培养策略[J].药学教育, 2009,25(4):11-13.
16.孟康康,任亚超, 唐星,金凤珠.鲑鱼降钙素肺部干粉吸入剂的制备及含量影响因素的考察[J].沈阳药科大学学报, 2008,25(12):929-1020.
17.刘婷,关显桐,吕邵娃,李永吉.还原型谷胱甘肽与维生素C联用对黄褐斑的治疗作用[J].世界中西医结合杂志,2017,12(11):1481-1485+1538.
18.刘婷,付强,关显桐,吕邵娃,李永吉.还原型谷胱甘肽脂质体凝胶剂抗黄褐斑形成作用的研究[J].世界中西医结合杂志,2017,12(10):1345-1348.
19.马骏一,刘婷,刘婧昕,王瑛琦,孙爽,李永吉.丁香苦苷mPEG-PLGA纳米载药系统的制备及性质表征[J].中医药信息,2015,32(05):43-46.
20.马骏一,刘婷,吕邵娃,郭玉岩,冯宇飞,李永吉.丁香苦苷单体与丁香苦苷PEG-PLGA纳米粒在大鼠体内药动学比较研究[J].中医药信息,2015,32(02):27-31.
21.封文静,刘婷,李永吉,吕邵娃.丁香苦苷PEG-PLGA纳米载药系统的制备及性质表征[J].中医药学报,2014,42(04):27-30.
[教学任务]
本科生:《中药药剂学》、《中药药剂学实验》、《药剂学》、《药剂学实验》、《分子药剂学》、《制剂工程学》、《药用高分子材料学》、《生物药剂学与药代动力学》、《中药新药研究与开发》、《现代给药系统》、《药事管理学》、《制剂设备及车间工艺设计》、《专业综合实验》、《专业知识拓展讲座》
专科生:《药剂学》、《药事管理学》、《药品质量管理》
[教材论著编写]
《组织学技术》
《药剂学实验》
《执业药师思维导图》
《药物制剂技术》
《药事管理学》